Ignite Creation Date:
2024-05-06 @ 10:11 AM
Last Modification Date:
2024-10-26 @ 12:26 PM
Study NCT ID:
NCT03182244
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-07-01
First Post:
2017-06-08
Brief Title:
A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia AML With FLT3 Mutation
Sponsor:
Astellas Pharma Inc
Organization:
Astellas Pharma Inc
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-01-15
Start Date Type:
ACTUAL
Primary Completion Date:
2023-12-25
Primary Completion Date Type:
ACTUAL
Completion Date:
2026-03-31
Completion Date Type:
ESTIMATED
First Submit Date:
2017-06-08
First Submit QC Date:
June 8 2017
Study First Post Date:
2017-06-09
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-08-28
Last Update Post Date:
2024-07-01
Last Update Post Date Type:
ACTUAL